Item 7.01. Regulation FD Disclosure.

On January 21, 2020, Progenics Pharmaceuticals, Inc. (the "Company") issued a press release providing an update on the ongoing strategic review by its reconstituted Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.






(d)     Exhibits.



 Exhibit No.                                    Document

     99.1          Press Release providing update on ongoing strategic review by
                 reconstituted Board of Directors, dated January 21, 2020

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses